Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down After Analyst Downgrade

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down prior to trading on Wednesday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The stock had previously closed at $17.92, but opened at $17.26. Daiichi Sankyo shares last traded at $18.1650, with a volume of 3,337 shares changing hands.

Separately, Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $33.74 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.91 and a beta of -0.11. The stock’s 50-day simple moving average is $17.81 and its two-hundred day simple moving average is $17.16.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities research analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.